BlinkLab news

Read BlinkLab's latest company news, research updates, partnerships, and media mentions.

Latest announcement

European ADHD Study Delivers Positive Results

European ADHD study supports expansion of diagnostic platform beyond autism

•
August 5, 2026

In the media

View all
August 5, 2026

BlinkLab Reports Positive ADHD Study Results to Expand AI Diagnostic Platform

Read the article
August 5, 2026

BlinkLab Achieves 82% Sensitivity and 83% Specificity in European ADHD Digital Biomarker Study

Read the article
July 14, 2026

BlinkLab expands clinical study portfolio beyond autism diagnostics

Read the article
May 26, 2026

Healthcare innovation pours into the Yarra Valley

Read the article

BlinkLab news

Regulatory Progress
Partnerships
Research
Company

Expansion of Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement – Drexel Univerisity

BlinkLab announced that Drexel University has joined as a clinical site for the Company’s pivotal U.S. regulatory trial for BlinkLab Dx 1.

Feb 12, 2026

BlinkLab Invited to Present at Simons Foundation Autism Research Initiative (SFARI) Event

Managing Director & CEO of BlinkLab Limited, Dr Henk-Jan Boele, has been invited to speak at a prestigious in-person scientific workshop hosted by the SimonsFoundation Autism Research Initiative (SFARI) in New York City, USA.

Jan 23, 2026

BlinkLab Receives $822,205 R&D Tax Incentive Refund

BlinkLab receives R&D Tax Incentive Refund relating to its U.S. Pilot Study and Australian clinical research initatives

Jan 8, 2026

High-Profile Journal Publication Validates BlinkLab's Technology

High-profile publication in leading journal "Autism Research" validates BlinkLab’s technology, providing support for future clinical adoption

Jan 5, 2026

Rush University Medical Center Joins BlinkLab’s Pivotal U.S. Autism Diagnostic Trial

BlinkLab announces Rush as eighth premier U.S. autism center for F1DA 510(k) trial of smartphone-based diagnostic aid, with first expected subjects in Q1 2026.

Nov 13, 2025

Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial

BlinkLab Dx 1 achieved 83.7% sensitivity and 84.7% specificity in a clinically diverse pediatric population, confirming robust real-world diagnostic performance.

Oct 22, 2025

Want to feature BlinkLab?

If you want to request an interview, need any assets or insights, feel free to reach out to BlinkLab's CEO, Henk-Jan Boele.

Send an email